Estimates the Quantile Treatment Effect on the Treated (QTT)
and Average Treatment Effect on the Treated (ATT) under a lagged-outcome
unconfoundedness assumption with staggered treatment adoption. The key
identifying assumption is
\(Y_{g,t}(0) \perp D \mid X, Y_{\text{pre}}\), i.e., conditional on
observed covariates and the pre-treatment outcome, treatment is as good
as randomly assigned within each cohort-period cell.
Estimation operates at the (g,t) level: for each cohort \(g\) and
post-treatment period \(t\), a cross-sectional comparison is made
between the treated group and a not-yet-treated (or never-treated)
comparison group, adjusting for covariates and (optionally) the
pre-treatment outcome. Group-time estimates are then aggregated to
overall, dynamic, and group-specific summaries.
Three estimation methods are available:
"ipw"
Propensity-score reweighting. Control units are
reweighted by \(\hat p(X,Y_{\text{pre}})/(1-\hat p(X,Y_{\text{pre}}))\)
to approximate the covariate distribution of the treated group.
"or"
Outcome regression. A quantile regression model is
fit on control units' post-period outcomes as a function of
\((X, Y_{\text{pre}})\), then predicted at treated units to
construct the counterfactual distribution (Melly 2006;
Chernozhukov, Fernandez-Val, and Melly 2013).
"aipw"
Doubly-robust augmented IPW. Combines the
propensity score and outcome models. Consistent if either model is
correctly specified.
When lagged_outcome_cov = FALSE and xformula = ~1, all
three methods reduce to a simple distribution comparison within each
(g,t) cell, which is consistent under unconditional unconfoundedness.
The ATT analogue (without the QTT) for staggered adoption under
lagged-outcome unconfoundedness is developed in Callaway (2023).